Covalon Technologies Ltd. · TSXV:COV
Covalon Technologies — Shareholder Meeting (March 2024)
17 slides from Covalon Technologies's shareholder meeting presentation, Mar 6, 2024
Slide 1: Management Presentation
Management Presentation Brent Ashton Chief Executive Officer TSX-V: COV OTCQX: CVALF info@covalon.com
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements included in this presentation may be considered forward-looking statements. These forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan”, “estimate”, “e
Slide 3: Covalon is a patient-driven medical device company
Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions that aim to help reduce pain, prevent infection, and promote healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection control, and
Slide 4: One Covalon
One Covalon Brent Ashton Dr. Val DiTizio Kim Crooks Ron Hebert Greg Leszczynski Katie Martinovich CEO Chief Scientific Officer SVP - Operations SVP - Growth VP - HR Interim CFO Dr. Katherine Evely Christina Mitchell Thys Muller Hector Padilla Teresa Sanelli Dr. Daryl Elaine Zhang Sr. Director, Clini
Slide 5: Covalon Innovation Has Created 3 Focused Business Platforms
Covalon Innovation Has Created 3 Focused Business Platforms Advanced Wound Care Infection Control* Medical Device Coatings Collagen Matrix Dressings Vascular Access & Post-Operative Dressings and Solutions Market Segment Size $10.8B** $9.9B** $12.9B** Market Segment Revenue CAGR 4.8% 5.3% 8.0% (2023
Slide 6: Helping Clinicians Solve Healthcare's Biggest Challenges
Helping Clinicians Solve Healthcare’s Biggest Challenges Healthcare Acquired Infections (HAIs) Vascular Access-driven Bloodstream Infections (CLABSIs and beyond) Catheter-Associated Urinary Tract Infections (CAUTIs) Surgical Site Infections (SSIs) Chronic Non-Healing Wounds Pressure Ulcers (PUs), Di
Slide 7: Favorable Trends
Favorable Trends Shift from CLABSI to Medical Adhesive-Related Clinical practice guidelines Increasing focus on Supply Hospital-Onset Bacteremia Skin Injuries (MARSI) driving change Chain Resiliency (HOB) Greater focus on Health Care providers are Stronger focus on Reducing sole-source preventing bl
Slide 8: Covalon Leads with Differentiated Solutions
Covalon Leads with Differentiated Solutions Collagen Matrix Dressing World’s only silicone IV dressing Available with or with dual antimicrobials without antimicrobial silver Acrylic-free adhesive dressing Unique formulation with EDTA, Transparent dressing allows for CMC and Alginate complete insert
Slide 9: Covalon's Value is Recognized by Leading Providers
Covalon’s Value is Recognized by Leading Providers Strong relationships with leading Children’s Hospitals Solid progress made with leading health systems both in the United States and Internationally 18
Slide 10: 2023 Highlights
2023 Highlights Covalon products utilized by Expanded 6 of the top 10 Impactful Key Opinion Leader Partnership with AVA U.S. Children’s Hospitals (KOL) and Webinar Programs IV Clear named Vascular Partnered with dEBra of Access Dressing of Choice America by donating in two major influential VALGuard
Slide 11: Annual Revenue Profile and Margin
Annual Revenue Profile and Margin 30.0 60% 54% 50% 47% YoY revenue growth for FY 25.0 41% 7.7 50% 2023 20.0 40% Strong Gross Margin 15.0 6.9 6.0 30% improvement 10.0 18.8 20% Progress towards positive 5.0 12.7 12.1 10% EBITDA - 0% FY2021 FY2022 FY2023 USA International Gross Margin % Strong Increase
Slide 12: Strong Balance Sheet
Strong Balance Sheet Sept. 30, Sept. 30, Dec. 31, 2022 2023 2023 Cash $14.1M $8.8M $8.3M Over $8.0 million of cash Current Assets $27.2M $21.3M $18.6M Total Assets $30.4M $24.9M $22.3M Zero debt Debt $---- $---- $---- Current Liabilities ($4.5M) ($5.2M) ($3.9M) Solid Current Ratio of 4.1 Total Liabi
Slide 13: Foundational Moves to Strengthen Covalon
Foundational Moves to Strengthen Covalon Quality & Financial Operational Commercial Regulatory Debt-free capital New Operations Implementing Consolidated structure Leader with deep broad-based strong Commercial teams expertise quality culture Cost discipline and Investments in prioritization of high
Slide 14: Looking Ahead
Looking Ahead FY 2024 Performance Short Term Directionality Long Term Optionality Strong revenue growth Laser focus on US Wound Care New leadership assessing future and Vascular Access value strategy capture Positive EBITDA for the year Reinvigorating broad-based Ramping up Eastgate production innov
Slide 15: Key Takeaways
Key Takeaways Covalon operates in large, growing MedTech segments with favorable trends. Our products are differentiated and solve real clinical challenges for our customers. Our fiscal year 2024 is focused on delivering on our financial commitments, investing in foundational elements to ensure our
Slide 16: Q&A
Q&A covalon TECHNOLOGIES LTD.
Slide 17: www.covalon.com I info@covalon.com
www.covalon.com I info@covalon.com
Covalon Technologies — Shareholder Meeting (March 2024) on 6ix